文献速递肝病

非肝硬化NAFLD中被忽视的亚临床门脉高压:是否真实及如何测量

Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
PubMed 文献 · J Hepatol · 2021-10-02

本文讨论非酒精性脂肪性肝病(NAFLD)中亚临床门脉高压的检测、程度和病理生物学。肝静脉压力梯度(HVPG)在NASH相关肝硬化中可能低估门脉压力,非肝硬化肝脏中更不准确。亚临床门脉高压(HVPG 6.0-9.5 mmHg)可在无肝硬化甚至无显著纤维化的NAFLD患者中反复检出,其对结局的影响尚不明确。

要点

  • HVPG在NASH相关肝硬化中可能低估门脉压力,非肝硬化时更不准确。
  • 亚临床门脉高压(HVPG 6.0-9.5 mmHg)可见于无肝硬化或显著纤维化的NAFLD患者。
  • 亚临床门脉高压对疾病结局的影响尚不明确,机制可能涉及机械化学信号通路。

核心结论

  • NAFLD中亚临床门脉高压可在无肝硬化或显著纤维化时被检出,但HVPG测量准确性有限且结局影响不明。

主要发现

  • HVPG在NASH相关肝硬化中可能低估门脉压力,非肝硬化肝脏中不准确性更可能发生。
  • 亚临床门脉高压定义为HVPG 6.0-9.5 mmHg,已在无肝硬化或显著纤维化的NAFLD患者中反复检出。
  • 临床显著门脉高压(HVPG ≥10 mmHg)在NASH中保持预后意义。
  • 肝细胞机械化学信号通路提示亚临床门脉高压不良效应的分子基础,并提示门脉压力与纤维化之间的双向关系。

关键数值与推荐

  • 亚临床门脉高压:HVPG 6.0-9.5 mmHg。
  • 临床显著门脉高压:HVPG ≥10 mmHg,在NASH中保持预后意义。

临床怎么用

  • 需关注NAFLD患者中亚临床门脉高压的存在,并探索新的、优选无创的测量方法以改善风险评估。

局限性

  • 亚临床门脉高压对疾病结局的影响尚不明确。
  • HVPG在非肝硬化肝脏中测量不准确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical and experimental advances related to the detection, magnitude and pathobiology of subclinical portal hypertension in non-alcoholic fatty liver disease (NAFLD), primarily observed in the presence of non-alcoholic steatohepatitis (NASH), prompt us to revisit current disease paradigms. Hepatic venous pressure gradient (HVPG) has been reported to underestimate portal pressure in NASH-related cirrhosis, while inaccuracy is more likely in non-cirrhotic livers, indicating a potential need for new and preferably non-invasive methods of measurement. Although clinically significant portal hypertension (HVPG ≥10 mmHg) retains its prognostic significance in NASH, subclinical portal hypertension (HVPG 6.0-9.5 mmHg) has been repeatedly detected in patients with NAFLD in the absence of cirrhosis or even significant fibrosis whereas the impact of these findings on disease outcomes remains unclear. Mechanocrine signalling pathways in various types of liver cell reveal a molecular basis for the adverse effects of subclinical portal hypertension and suggest a bidirectional relationship between portal pressure and fibrosis. These findings may guide efforts to improve risk assessment and identify novel therapeutic targets in NAFLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Baffy G, Bosch J. Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it? J Hepatol. 2021. PMID: 34606912. doi:10.1016/j.jhep.2021.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。